ProMIS Neurosciences (PMN) Return on Capital Employed (2022 - 2026)
ProMIS Neurosciences' (PMN) quarterly Return on Capital Employed came in at 130.62% in Q1 2026, up 3800.0% YoY from 3.35% in Q1 2025, and up 84.05% on a QoQ basis from 819.0% in Q4 2025.
ProMIS Neurosciences (PMN) Return on Capital Employed (2022 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 5 years of Return on Capital Employed data on file, last reported at 130.62% in Q1 2026.
- Quarterly Return on Capital Employed rose 3800.0% year-over-year to 130.62% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 130.62% (up 3800.0% YoY) and the FY2025 annual result came in at 1105.88%, down 98609.0% from the prior year.
- Return on Capital Employed improved to 130.62% in Q1 2026, from 819.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11505.52% in Q3 2023 to a low of 1601.02% in Q2 2025.
- A 5-year average of 1243.72% and a median of 142.37% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 1191955 bps — and 2024, when it slumped 1164789 bps.
- Tracing PMN's Return on Capital Employed over 5 years: stood at 8996.13% in 2022, then tumbled by 102 bps to 222.93% in 2023, then surged by 61 bps to 86.33% in 2024, then plunged by 849 bps to 819.0% in 2025, then soared by 84 bps to 130.62% in 2026.
- The last three Return on Capital Employed figures came in at 130.62% (Q1 2026), 819.0% (Q4 2025), and 1081.58% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 7.88% |
| 10 | ProMIS Neurosciences | 135.63 Mn | 82.16 Mn | - | -79.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.27% |
| Mar 31, 2026 | -130.62% |
| Dec 31, 2025 | -819.00% |
| Sep 30, 2025 | -1,081.58% |
| Jun 30, 2025 | -1,601.02% |
| Mar 31, 2025 | -168.63% |
| Dec 31, 2024 | -86.33% |
| Sep 30, 2024 | -142.37% |
| Jun 30, 2024 | 1,844.50% |
| Mar 31, 2024 | -218.41% |
| Dec 31, 2023 | -222.93% |
| Sep 30, 2023 | 11,505.52% |
| Jun 30, 2023 | 388.64% |
| Mar 31, 2023 | 805.91% |
| Dec 31, 2022 | 8,996.13% |
| Sep 30, 2022 | -414.03% |